Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10

PURPOSE: Patients with human epidermal growth factor receptor 2 (HER2)–positive metastatic breast cancer eventually develop resistance to dual-antibody therapy with trastuzumab plus pertuzumab. Mechanisms of resistance have not been well elucidated. We evaluated the safety, tolerability, and efficac...

Descripción completa

Detalles Bibliográficos
Autores principales: Abraham, Jame, Montero, Albert J., Jankowitz, Rachel C., Salkeni, Mohamad Adham, Beumer, Jan H., Kiesel, Brian F., Piette, Fanny, Adamson, Laura M., Nagy, Rebecca J., Lanman, Richard B., Sperinde, Jeff, Huang, Weidong, Allegra, Carmen J., Srinivasan, Ashok, Wang, Ying, Pogue-Geile, Katherine L., Lucas, Peter C., Jacobs, Samuel A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2019
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6784849/
https://www.ncbi.nlm.nih.gov/pubmed/31442103
http://dx.doi.org/10.1200/JCO.19.00858

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6784849/
https://www.ncbi.nlm.nih.gov/pubmed/31442103
http://dx.doi.org/10.1200/JCO.19.00858

Ejemplares similares